+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Comments

Loading...

Ascendis Pharma

ASNDNASDAQ

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$135.16

-1.16-0.85%

Last update: 10:39 AM

15 minutes delayed

Ascendis Pharma (ASND) Forecast

News

Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Ascendis Pharma (NASDAQ:ASND) Stock

Ascendis Pharma Stock (NASDAQ: ASND)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, July 18, 2024

$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
Benzinga Insights

Friday, July 05, 2024

Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday
Avi Kapoor
Reported Thursday, Pendopharm Partners With A...
Benzinga Newsdesk

Wednesday, July 03, 2024

Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
Benzinga Insights

Wednesday, June 26, 2024

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
Benzinga Insights

Tuesday, June 25, 2024

TD Cowen Upgrades Ascendis Pharma to Buy, Rai...
Benzinga Newsdesk

Monday, June 24, 2024

Ascendis Reports Presentation Of Data From Ph...
Benzinga Newsdesk

Monday, June 03, 2024

Ascendis Pharma To Present New Data And Updat...
Benzinga Newsdesk

Friday, May 31, 2024

If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today
Benzinga Insights
Stifel Initiates Coverage On Ascendis Pharma ...
Benzinga Newsdesk

Tuesday, May 28, 2024

(ASND) - Analyzing Ascendis Pharma's Short Interest
Benzinga Insights

Friday, May 17, 2024

$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today
Benzinga Insights

Thursday, May 16, 2024

Morgan Stanley Maintains Equal-Weight on Asce...
Benzinga Newsdesk

Wednesday, May 15, 2024

FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
Vandana Singh
Cantor Fitzgerald Reiterates Overweight on As...
Benzinga Newsdesk

Tuesday, May 14, 2024

FDA Extends Review Period For Ascendis Pharma...
Benzinga Newsdesk

Monday, May 13, 2024

Ascendis Pharma Announces 2-Year Results From...
Benzinga Newsdesk

Thursday, May 09, 2024

Ascendis Pharma A/S Clinical And Quality-Of-L...
Benzinga Newsdesk

Monday, May 06, 2024

$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
Benzinga Insights

Friday, May 03, 2024

Wells Fargo Maintains Overweight on Ascendis ...
Benzinga Newsdesk
JP Morgan Maintains Overweight on Ascendis Ph...
Benzinga Newsdesk
Cantor Fitzgerald Reiterates Overweight on As...
Benzinga Newsdesk

Thursday, May 02, 2024

Ascendis Pharma Q1 Sales €95.894M Beat €79.49...
Benzinga Newsdesk

Friday, April 26, 2024

Looking Into Ascendis Pharma's Recent Short Interest
Benzinga Insights

Wednesday, April 24, 2024

MHRA Approves YORVIPATH In Great Britain For ...
Benzinga Newsdesk

Monday, April 22, 2024

Morgan Stanley Maintains Equal-Weight on Asce...
Benzinga Newsdesk

Thursday, April 18, 2024

$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on As...
Benzinga Newsdesk

Friday, April 12, 2024

Ascendis Pharma's Options Frenzy: What You Need to Know
Benzinga Insights

Wednesday, April 03, 2024

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Benzinga Insights

Tuesday, April 02, 2024

JP Morgan Maintains Overweight on Ascendis Ph...
Benzinga Newsdesk

Monday, April 01, 2024

Cantor Fitzgerald Reiterates Overweight on As...
Benzinga Newsdesk

Friday, March 15, 2024

Wells Fargo Maintains Overweight on Ascendis ...
Benzinga Newsdesk

Thursday, March 14, 2024

Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
Benzinga Insights

Sunday, March 03, 2024

These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher
Bibhu Pattnaik

Friday, February 23, 2024

$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today
Benzinga Insights

Tuesday, February 13, 2024

How Is The Market Feeling About Ascendis Pharma?
Benzinga Insights

Thursday, February 08, 2024

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 Today
Benzinga Insights
Citigroup Maintains Buy on Ascendis Pharma, R...
Benzinga Newsdesk
Wedbush Maintains Outperform on Ascendis Phar...
Benzinga Newsdesk

Wednesday, February 07, 2024

Ascendis Pharma Q4 2023 GAAP EPS $(1.66) Miss...
Benzinga Newsdesk
Earnings Scheduled For February 7, 2024
Benzinga Insights

Tuesday, February 06, 2024

Ascendis Pharma's Earnings: A Preview
Benzinga Insights
Cantor Fitzgerald Maintains Overweight on Asc...
Benzinga Newsdesk

Friday, February 02, 2024

$100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth This Much Today
Benzinga Insights

Monday, January 29, 2024

Ascendis Pharma Announces Formation And Launc...
Benzinga Newsdesk

Tuesday, January 09, 2024

Er-Kim Announces Exclusive Distribution Agree...
Benzinga Newsdesk

Monday, January 08, 2024

Vector Pharma FZCO Enters Exclusive Distribut...
Benzinga Newsdesk
Ascendis Pharma Introduces Vision 2030; Preli...
Benzinga Newsdesk

Sunday, January 07, 2024

Specialised Therapeutics Signs Exclusive Agreement With Ascendis Pharma For Distribution And Commercialization Of Three Endocrinology Therapies In Australia And Select South-East Asia Countries
Charles Gross

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved